EU Drug Regulators Seek Help To Shape Network's Future Until 2028

More details on how the EU network of medicines agencies plan to leverage AI and foster competitiveness is now available in their draft 2025-2028 strategy, which they have published for comment.

The EU medicines agencies network is to finalize its strategy to 2028 soon • Source: Shutterstock

The EU network of medicines agencies has given pharmaceutical stakeholders until 30 November to share their views on its planned strategy to 2028 so they can “help shape the direction of the network for the next few years.”

Key Takeaways

The European Medicines Agency and the EU’s Heads of Medicines Agencies are seeking feedback on their planned strategy for 2025-2028.

The draft strategy, published this week by the European Medicines Agency and the EU’s Heads of Medicines Agencies, updates...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

25 Jul 2025

• By Eliza Slawther and Neena Brizmohun

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

25 Jul 2025

• By Neena Brizmohun

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

25 Jul 2025

• By Eliza Slawther and Sarah Karlin-Smith

The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

24 Jul 2025

• By Vibha Sharma

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

24 Jul 2025

• By Derrick Gingery

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.